Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

Fig. 1

The association between Gal9 and TIM-3 as prognostic marker for Selinexor + HiDAC Mito regimen. At time of diagnosis, multi-parameter flow-cytometry was performed on bone marrow (BM) aspirates from 26 patients. A FITC conjugated anti-CD34 antibody was used to analyze frequencies of CD34+ AML cells and the remaining CD34βˆ’ cell populations. (a) Patients were divided into 2 cohorts - those who achieved CR (n = 16), and those who experienced TF (n = 10). The comparison of frequency of CD4+ PD-1+ T cells and CD34βˆ’Gal-9+ in these two groups are shown. (b-c) Bars represent medians. Percentage of cumulative frequencies are displayed in (e) and (f). We calculated the Spearman correlation coefficients to describe associations between CD4+PD-1+ T cells and CD34+PDL-1+ AML cells in TF patients (d); same for CD34-Gal-9+ between inhibitory and activator markers TIM-3, ICOS, Lag3 on CD8+ cells, at time of diagnosis (g). Lastly, between CD8+TIM-3+ and ICOS and Lag-3. (h) A linear regression according to the Deming procedure and deviation for linearity (Runs Test) was additionally computed. Gal-9 and TIM-3 vs HLA-DR was used as negative control.(i)

Back to article page